Back to Search
Start Over
Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma
- Source :
- Digital.CSIC. Repositorio Institucional del CSIC, instname
- Publication Year :
- 2008
- Publisher :
- American Association for Cancer Research, 2008.
-
Abstract
- et al.<br />Cholesterol metabolism is deregulated in carcinogenesis, and cancer cells exhibit enhanced mitochondrial cholesterol content whose role in cell death susceptibility and cancer therapy has not been investigated. Here, we describe that mitochondria from rat or human hepatocellular carcinoma (HC) cells (HCC) or primary tumors from patients with HC exhibit increased mitochondrial cholesterol levels. HCC sensitivity to chemotherapy acting via mitochondria is enhanced upon cholesterol depletion by inhibition of hydroxymethylglutaryl-CoA reductase or squalene synthase (SS), which catalyzes the first committed step in cholesterol biosynthesis. HCC transfection with siRNA targeting the steroidogenic acute regulatory protein StAR, a mitochondrial cholesterol–transporting polypeptide which is overexpressed in HCC compared with rat and human liver, sensitized HCC to chemotherapy. Isolated mitochondria from HCC with increased cholesterol levels were resistant to mitochondrial membrane permeabilization and release of cytochrome c or Smac/DIABLO in response to various stimuli including active Bax. Similar behavior was observed in cholesterol-enriched mitochondria or liposomes and reversed by restoring mitochondrial membrane order or cholesterol extraction. Moreover, atorvastatin or the SS inhibitor YM-53601 potentiated doxorubicin-mediated HCC growth arrest and cell death in vivo. Thus, mitochondrial cholesterol contributes to chemotherapy resistance by increasing membrane order, emerging as a novel therapeutic niche in cancer therapy.<br />Grant support: Research Center for Liver and Pancreatic Diseases Grant P50 AA 11999 funded by the US National Institute on Alcohol Abuse and Alcoholism; Plan Nacional de I+D Grants SAF2005-03923, SAF2005-03943, SAF2006-06780, BFU2005-06095, and FIS06/0395; the Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas supported by the Instituto de Salud Carlos III; the Ramon y Cajal Research Program (Ministry of Education and Science; A. Colell and A. Morales); and a predoctoral fellowship from the Basque Government (O. Terrones).
- Subjects :
- Male
Cancer Research
medicine.medical_specialty
Programmed cell death
Carcinoma, Hepatocellular
StAR
Mice, Nude
Mitochondrial membrane permeabilization
Antineoplastic Agents
Mitochondria, Liver
Mitochondrion
Biology
medicine.disease_cause
Mice
chemistry.chemical_compound
Squalene synthase inhibitor
Tumor xenografts
Internal medicine
medicine
Animals
Humans
Gene Silencing
RNA, Small Interfering
Inner mitochondrial membrane
Cells, Cultured
Aged
Mice, Inbred BALB C
Cholesterol
Steroidogenic acute regulatory protein
Liver Neoplasms
Statins
Transfection
Middle Aged
Phosphoproteins
Xenograft Model Antitumor Assays
digestive system diseases
Rats
Farnesyl-Diphosphate Farnesyltransferase
Endocrinology
Oncology
chemistry
Drug Resistance, Neoplasm
Cancer cell
Cancer research
lipids (amino acids, peptides, and proteins)
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Carcinogenesis
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Digital.CSIC. Repositorio Institucional del CSIC, instname
- Accession number :
- edsair.doi.dedup.....ed6146bdf3d8da2f1ce1930a06bd5112